摘要
本文综述了定义IIa类HDAC蛋白和化合物选择性靶向其酶催化结构域(CD)的表型的关键文献。研究重点是IIa类HDACs在体内和体外生理和病理条件下的作用,以及它们在调节基因、上游蛋白和信号通路中的作用模式。表型研究进一步表明,沉默选定的IIa类HDACs或其酶学特性,可能是有益的,也可能是有害的。我们也总结了从CD抑制剂的构效关系中获得的知识,以及在晶体结构或模型研究中支持同工酶选择性的分子机制。考虑到IIa类HDACs沉默所影响的基因数量远小于I类,基因调控IIa类HDACs的作用可能更具选择性。由于IIa类HDACs限制了组织分布和独立于CD的多种功能,因此靶向IIa类HDACs的CD可以产生比其他HDAC配体更有选择性的治疗药物,而且副作用明显更少。
关键词: 药物发现,表观遗传调控,表型,组蛋白去乙酰化酶,HDAC异构体,IIa类HDAC,抑制剂,催化域抑制剂。
Current Medicinal Chemistry
Title:Targeting Class IIa HDACs: Insights from Phenotypes and Inhibitors
Volume: 28 Issue: 42
关键词: 药物发现,表观遗传调控,表型,组蛋白去乙酰化酶,HDAC异构体,IIa类HDAC,抑制剂,催化域抑制剂。
摘要: This review summarizes key literature defining the phenotypes of individual class IIa HDAC proteins and compounds that selectively target their enzymatic catalytic domain (CD). The focus is on the effects of class IIa HDACs in physiological and pathological conditions, both in vitro and in vivo, and on their mode of action in regulating genes, upstream proteins and signaling pathways. Phenotype studies further demonstrate either beneficial or detrimental effects of silencing selected class IIa HDACs or their enzymatic properties. We also summarize the knowledge gained from structure-activity relationships of CD inhibitors as well as molecular mechanisms underpinning isozyme selectivity where crystal structures or modelling studies are available. Given that the number of genes affected by silencing class IIa HDACs is much smaller than class I, the role of gene regulation of class IIa HDACs could be much more selective. Since class IIa HDACs have restricted tissue distributions and multiple functions independent of their CD, targeting the CD of class IIa HDACs could lead to more selective therapeutic agents with significantly fewer side-effects than other HDAC ligands.
Export Options
About this article
Cite this article as:
Targeting Class IIa HDACs: Insights from Phenotypes and Inhibitors, Current Medicinal Chemistry 2021; 28 (42) . https://dx.doi.org/10.2174/0929867328666210629160647
DOI https://dx.doi.org/10.2174/0929867328666210629160647 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Risk and Endothelial Dysfunction: The Preferential Route for Atherosclerosis
Current Pharmaceutical Biotechnology Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Local Anesthetis and Adjuvants in Pediatric Regional Anesthesia
Current Drug Targets Complement and Complement Regulatory Proteins as Potential Molecular Targets for Vascular Diseases
Current Pharmaceutical Design Intracellular Signaling Triggered by Formyl-Peptide Receptors in Nonphagocytic Cells
Current Signal Transduction Therapy CRP Pro-inflammatory Signalling in Atherosclerosis: Myth or Reality?
Current Signal Transduction Therapy Efficacy and Safety of Mesenchymal Stromal Cells Therapy for COVID-19 Infection: A Systematic Review and Meta-analysis
Current Stem Cell Research & Therapy Treatment of Hypertensive Complications in Pregnancy
Current Pharmaceutical Design Stem Cell Therapy in Chronic Obstructive Pulmonary Disease. Seeking the Prometheus Effect
Current Drug Targets Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets New Insights into the Intracellular Mechanisms by Which PGI2 Analogues Elicit Vascular Relaxation: Cyclic AMP-Independent, Gs-Protein Mediated-Activation of MaxiK Channel
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Endothelial Dysfunction in the Hypertensive State: Mechanisms of Hypertensive Cardiovascular Complications
Current Hypertension Reviews Insulin-Like Growth Factor-1 and its Derivatives: Potential Pharmaceutical Application for Ischemic Brain Injury
Recent Patents on CNS Drug Discovery (Discontinued) Ischemic and Oxidative Damage to the Hypothalamus May Be Responsible for Heat Stroke
Current Neuropharmacology Platelet Aggregation and Exogenous Factors From Animal Sources
Current Drug Targets - Cardiovascular & Hematological Disorders Advances in Coronary Stent Technology - Active Drug-Loaded Stent Surfaces for Prevention of Restenosis and Improvement of Biocompatibility
Current Pharmaceutical Biotechnology Catalytic Features, Regulation and Function of Myocardial Phospholipase A2
Current Medicinal Chemistry - Cardiovascular & Hematological Agents In vivo Optical Molecular Imaging of Cardiovascular Diseases: Long Road Ahead
Current Molecular Imaging (Discontinued) Variability in the Response to Non-pharmacological Treatments in Patients with Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine The Role of Integrin-Mediated Cell Adhesion in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Pharmaceutical Design